384 related articles for article (PubMed ID: 16397261)
1. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J
Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261
[TBL] [Abstract][Full Text] [Related]
2. A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells.
Yim D; Singh RP; Agarwal C; Lee S; Chi H; Agarwal R
Cancer Res; 2005 Feb; 65(3):1035-44. PubMed ID: 15705905
[TBL] [Abstract][Full Text] [Related]
3. Decursin suppresses human androgen-independent PC3 prostate cancer cell proliferation by promoting the degradation of beta-catenin.
Song GY; Lee JH; Cho M; Park BS; Kim DE; Oh S
Mol Pharmacol; 2007 Dec; 72(6):1599-606. PubMed ID: 17855653
[TBL] [Abstract][Full Text] [Related]
4. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
5. Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents.
Lu J; Kim SH; Jiang C; Lee H; Guo J
Acta Pharmacol Sin; 2007 Sep; 28(9):1365-72. PubMed ID: 17723170
[TBL] [Abstract][Full Text] [Related]
6. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
Murthy S; Agoulnik IU; Weigel NL
Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of proliferation and expression of AR/PSA by herbal supplement Equiguard in LNCaP cells cultured in androgen-proficient FBS and androgen-deficient charcoal-stripped FBS is correlated with increased serine-15 phosphorylation of the tumor suppressor gene p53.
Lu X; Guo J; Hsieh TC; Wu JM
Anticancer Res; 2003; 23(3B):2489-98. PubMed ID: 12894532
[TBL] [Abstract][Full Text] [Related]
9. Piper cubeba targets multiple aspects of the androgen-signalling pathway. A potential phytotherapy against prostate cancer growth?
Yam J; Kreuter M; Drewe J
Planta Med; 2008 Jan; 74(1):33-8. PubMed ID: 18080233
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
Chiu FL; Lin JK
Prostate; 2008 Jan; 68(1):61-71. PubMed ID: 18008333
[TBL] [Abstract][Full Text] [Related]
11. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
Jackson KM; Frazier MC; Harris WB
Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
[TBL] [Abstract][Full Text] [Related]
12. Antiandrogen-like actions of an antioxidant on survivin, Bcl-2 and PSA in human prostate cancer cells.
Gunawardena K; Campbell LD; Meikle AW
Cancer Detect Prev; 2005; 29(4):389-95. PubMed ID: 16139439
[TBL] [Abstract][Full Text] [Related]
13. A novel class of pyranocoumarin anti-androgen receptor signaling compounds.
Guo J; Jiang C; Wang Z; Lee HJ; Hu H; Malewicz B; Lee HJ; Lee JH; Baek NI; Jeong JH; Kim DK; Kang KS; Kim SH; Lu J
Mol Cancer Ther; 2007 Mar; 6(3):907-17. PubMed ID: 17363485
[TBL] [Abstract][Full Text] [Related]
14. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
[TBL] [Abstract][Full Text] [Related]
15. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
16. A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo.
Zhang Y; Shaik AA; Xing C; Chai Y; Li L; Zhang J; Zhang W; Kim SH; Lü J; Jiang C
Invest New Drugs; 2012 Oct; 30(5):1820-9. PubMed ID: 21870073
[TBL] [Abstract][Full Text] [Related]
17. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
19. Zanthoxyli Fructus induces growth arrest and apoptosis of LNCaP human prostate cancer cells in vitro and in vivo in association with blockade of the AKT and AR signal pathways.
Yang Y; Ikezoe T; Takeuchi T; Adachi Y; Ohtsuki Y; Koeffler HP; Taguchi H
Oncol Rep; 2006 Jun; 15(6):1581-90. PubMed ID: 16685399
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
